Clinical Trials | May 28, 2024
Ascentage releases results from multiple clinical studies of its lead drug candidates
These abstracts report on the company's three lead drug candidates, including olverembatinib
These abstracts report on the company's three lead drug candidates, including olverembatinib
Updated results from the four studies will be presented in Oral Reports or Posters at the ASCO Annual Meeting
Submission based on results from pivotal phase III trial showing all primary endpoints met
PharmaLogic will assist ARTBIO with radiochemistry and supply of the finished radiopharmaceutical product for future Phase I and II clinical trials of AB001 from their facility in New York
Comprehensive clinical development programs being initiated for each investigational candidate
Aim is to treat Dyslipidemia by inhibiting PCSK9 with a novel entity
Exothera will manufacture Meissa’s MV-012-968 vaccine candidate under CGMP regulations to supply Phase 2 clinical trials
Study efficacy measures will include the expression of dystrophin protein and motor function.
The data from this study show that MM-II has the potential to provide durable pain relief for our patients
Projected ~US$100 million cash balance of combined company expected to fund operations through mid-2025 and to clinical data over the next 12 to 24 months
Subscribe To Our Newsletter & Stay Updated
